Enable JavaScript to ensure website accessibility
Precipio Announces The Resignation Of Samuel Riccitelli And The Introduction Of Richard Sandberg To Its Board Of Directors

Douglas Fisher, MD will assume the role of interim Chairman of the Board NEW HAVEN, [...]

Precipio Wins $750,000 Pharma Project

Testing and revenues will begin in Q4 and continue into Q1-2020 NEW HAVEN, CT, (November [...]

Precipio Reports Superior Performance For IV-Cell™ In Side-By-Side Analysis Conducted By Two Major External Laboratories

Testing yielded substantially better operational and clinical results, including the identification of a Leukemia missed when using [...]

Precipio Announces Q3-2019 Corporate Update Call For Shareholders

Conference Call to be held on Wednesday, November 13th, 2019 at 5:30 PM EST NEW [...]

Partners HealthCare And Precipio Enter Into Pathology Services Agreement

Continued Expansion of Academic Expertise Platform NEW HAVEN, CT, (October 9th, 2019) – Specialty diagnostics company Precipio, [...]

Precipio Announces Shareholder Update Call On Commercial Progress

Conference call to be held Thursday October 10th at 5:00PM EST NEW HAVEN, CT, (October [...]

Clinical Validations For IV-Cell™ And HemeScreen™ Completed

Orders expected from several major labs both domestically and internationally NEW HAVEN, CT, (September 26th, [...]

Precipio And University Of Pennsylvania Enter Into Joint Collaboration Agreement For Pathology Diagnostics

First cases already diagnosed and reported by Penn expert pathologists NEW HAVEN, CT, (September 5th, [...]

Precipio Pathology Sales Metrics Demonstrate Continuous Improvement In Q2 2019

Three key metrics indicate growth over prior Quarter and same Quarter of 2018 NEW HAVEN, [...]

Precipio Announces Q2-2019 Corporate Update Call For Shareholders

Conference Call to be held on Wednesday, August 21st, 2019 at 5:00 PM EST NEW [...]